Zentalis Pharmaceuticals (ZNTL) Asset Utilization Ratio (2024 - 2025)
Zentalis Pharmaceuticals (ZNTL) posted quarterly Asset Utilization Ratio of 0.08 for Q3 2025, down 8.07% year-over-year from 0.09 in Q3 2024, and up 8.36% quarter-over-quarter from 0.07 in Q2 2025.
Powered by 
Analysis
Zentalis Pharmaceuticals (ZNTL) Asset Utilization Ratio (2024 - 2025) Analysis & Trends
Zentalis Pharmaceuticals' Asset Utilization Ratio history runs 2 years deep, the most recent figure standing at 0.08 for Q3 2025.
- In Q3 2025, Asset Utilization Ratio fell 8.07% year-over-year to 0.08; the TTM figure through Sep 2025 stood at 0.08 (down 8.07% YoY), while the FY2024 annual figure was 0.14, changed N/A from the prior year.
- Asset Utilization Ratio for Q3 2025 stood at 0.08, up from 0.07 in the prior quarter.
- The five-year high for Asset Utilization Ratio was 0.15 in Q4 2024, with the low at 0.07 in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 0.47 |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 0.38 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 0.20 |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 0.69 |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 0.90 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 0.13 |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 0.54 |
| 10 | Zentalis Pharmaceuticals | 282.81 Mn | 282.81 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2025 | 0.08 |
| Jun 30, 2025 | 0.07 |
| Mar 31, 2025 | 0.07 |
| Dec 31, 2024 | 0.15 |
| Sep 30, 2024 | 0.09 |
| Jun 30, 2024 | 0.08 |
| Mar 31, 2024 | 0.07 |